Affinity Asset Advisors, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Affinity Asset Advisors, LLC disclosed 75 US equity positions worth $640.1m in its Q4 2024 13F filing. The largest position was XENE at 7.1% of the reported book, followed by APGE and ACLXGBX. Against the Q3 2024 filing, it opened 5 new positions, added to 22 and reduced 13 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | XENE XENON PHARMACEUTICALS INC | Healthcare | 7.1% | $45.5m | 1,161,237 | 2% | added |
| 2 | APGE APOGEE THERAPEUTICS INC | Healthcare | 6.6% | $42.2m | 931,728 | 40% | added |
| 3 | ACLXGBX ARCELLX INC | 5.1% | $32.6m | 425,000 | 6% | added | |
| 4 | ALKS ALKERMES PLC | Healthcare | 4.9% | $31.6m | 1,100,000 | 10% | added |
| 5 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 4.8% | $30.9m | 1,400,000 | 0% | held |
| 6 | VRNA VERONA PHARMA PLC | 4.8% | $30.7m | 660,000 | 2% | added | |
| 7 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 4.0% | $25.5m | 82,500 | -18% | reduced |
| 8 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 3.7% | $23.5m | 460,000 | 15% | added | |
| 9 | NUVALENT INC | 3.5% | $22.3m | 285,000 | -16% | reduced | |
| 10 | SYRE SPYRE THERAPEUTICS INC | 3.0% | $19.2m | 824,328 | 65% | added | |
| 11 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.9% | $18.6m | 1,500,000 | 7% | added |
| 12 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.9% | $18.4m | 1,095,924 | 13% | added | |
| 13 | VERA VERA THERAPEUTICS INC | Healthcare | 2.8% | $18.0m | 425,000 | -2% | reduced |
| 14 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.8% | $17.7m | 940,083 | 9% | added |
| 15 | MERUS N V | 2.6% | $16.4m | 389,241 | 141% | added | |
| 16 | COHERUS BIOSCIENCES INC | 2.5% | $16.2m | 16,625,000 | 0% | held | |
| 17 | OMEROS CORP | 2.3% | $14.6m | 15,525,000 | -28% | reduced | |
| 18 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 2.0% | $12.9m | 279,445 | -4% | reduced |
| 19 | ARVN ARVINAS INC | Healthcare | 1.9% | $12.1m | 630,000 | 180% | added |
| 20 | KARYOPHARM THERAPEUTICS INC | 1.9% | $11.9m | 15,250,000 | 24% | added | |
| 21 | INOZYME PHARMA INC | 1.7% | $11.0m | 3,972,318 | 41% | added | |
| 22 | NEWAMSTERDAM PHARMA COMPANY | 1.7% | $10.9m | 425,000 | -10% | reduced | |
| 23 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 1.7% | $10.6m | 4,500,000 | 0% | held |
| 24 | GERN GERON CORP | Healthcare | 1.2% | $8.0m | 2,250,000 | 50% | added |
| 25 | RZLT REZOLUTE INC | 1.2% | $7.7m | 1,575,000 | -7% | reduced | |
| 26 | PROQR THRAPEUTICS N V | 1.2% | $7.5m | 2,825,000 | – | new | |
| 27 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.1% | $7.1m | 368,698 | 5% | added |
| 28 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.0% | $6.3m | 75,000 | -6% | reduced |
| 29 | ERAS ERASCA INC | Healthcare | 1.0% | $6.3m | 2,499,431 | 0% | held |
| 30 | SLNOEUR SOLENO THERAPEUTICS INC | 0.9% | $5.8m | 130,000 | 420% | added | |
| 31 | TVTX TRAVERE THERAPEUTICS INC | 0.9% | $5.7m | 6,000,000 | 20% | added | |
| 32 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.9% | $5.6m | 300,000 | -8% | reduced |
| 33 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.9% | $5.5m | 200,000 | -33% | reduced |
| 34 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.8% | $5.0m | 130,000 | – | new |
| 35 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.7% | $4.3m | 350,000 | 0% | held |
| 36 | CATX PERSPECTIVE THERAPEUTICS INC | 0.6% | $4.1m | 1,300,000 | 160% | added | |
| 37 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.6% | $4.1m | 550,765 | 1124% | added |
| 38 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $3.6m | 350,000 | 0% | held | |
| 39 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.5% | $3.5m | 200,000 | – | new |
| 40 | INSM INSMED INC | Healthcare | 0.5% | $3.5m | 50,000 | 0% | held |
| 41 | NEWAMSTERDAM PHARMA COMPANY | 0.5% | $3.3m | 237,935 | 12% | added | |
| 42 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.5% | $3.2m | 850,512 | 183% | added |
| 43 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.5% | $3.2m | 263,817 | 0% | held |
| 44 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.5% | $3.1m | 159,614 | -70% | reduced |
| 45 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 0.5% | $2.9m | 70,742 | -6% | reduced |
| 46 | CGON CG ONCOLOGY INC | Healthcare | 0.4% | $2.9m | 100,000 | – | new |
| 47 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 0.4% | $2.7m | 58,331 | 0% | held |
| 48 | HELIX ACQUISITION CORP II | 0.4% | $2.6m | 250,000 | 0% | held | |
| 49 | OAKTREE ACQUISITION CORP III | 0.4% | $2.5m | 250,000 | – | new | |
| 50 | IMVT IMMUNOVANT INC | Healthcare | 0.4% | $2.5m | 100,000 | -56% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.